Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Autolus Therapeutics plcNASDAQ: AUTL

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 266.14M shares rose 0.0% year over year, in line with the +0.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +41.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +0.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
266.14M+0.0% QoQ
Last fiscal yearDec 2025
266.14M+4.3% YoY
LTMMar 2026
266.14M+0.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+4.3%——
3-year CAGR+41.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
266.14M USD
Year-over-year change
+4.3%
4-year CAGR
+38.6%

Weighted Avg Shares (Diluted) vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 weighted avg shares (diluted) of 266.14M shares is the highest of the 10 companies compared; the peer median is 94.18M shares.
  • Its year-over-year change of +0.0% is the lowest of 10, against a peer median of +4.3%.
  • Over three fiscal years its annual growth of +41.0% compares with a peer median of +15.4%.
AUTL Competitors Peer median
Weighted Avg Shares (Diluted) for AUTL and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.17M +49.9%+46.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +60.9%+63.6%
Peer median (excluding AUTL) 94.18M+4.3%+15.4%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.